.
.
Sažetak
Introduction: Lactate dehydrogenase (LDH) levels are predictive of coronavirus disease 2019 (COVID-19) severity. We investigated LDH isoenzyme levels to identify the tissue responsible for serum LDH elevation in patients with COVID-19.
Materials and Methods: Hospitalised COVID-19 patients with serum LDH levels exceeding the upper limit of normal were included. LDH isoenzymes were detected quantitatively on agarose gels. The radiological severity of lung involvement on computed tomography was scored as 0–5 for each lobe (total possible score, 0–25). Disease severity was determined using the World Health Organization (WHO) clinical progression scale.
Results: In total, 111 patients (mean age, 59.96 ± 16.14), including 43 females (38.7%), were enrolled. The serum levels of total LDH and all five LDH isoenzymes were significantly higher in the severe group. The levels of all LDH isoenzymes excluding LDH5 positively correlated with the WHO score. LDH3 levels correlated with chest computed tomography findings (r2 = 0.267, p = 0.005). On multivariate analysis, LDH3 was an independent risk factor for the deterioration of COVID-19.
Discussion: LDH3 appears to be an independent risk factor for deterioration in patients with COVID-19. LDH elevation in patients with COVID-19 predominantly resulted from lung, liver and muscle damage.
Reference
2. Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One 2020;15:e0241955.
3. Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med (CCLM) 2020;1(ahead-of-print).
4. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clin Infect Dis 2020;71:1393–9.
5. Shi J, Li Y, Zhou X, Zhang Q, Ye X, Wu Z, et al. Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMC Med 2020;18:168.
6. Chen XY, Huang MY, Xiao ZW, Yang S, Chen XQ. Lactate dehydrogenase elevations is associated with severity of COVID-19: a meta-analysis. Crit Care 2020;24:459.
7. McPherson RA, Pincus MR. Clinical enzymology. In: Henry JB, editor. Henry’s clinical diagnosis and management by laboratory methods e-book. St. Louis, MO: Elsevier Health Sciences; 2017.
8. Glick Jr JH. Serum lactate dehydrogenase isoenzyme and total lactate dehydrogenase values in health and disease, and clinical evaluation of these tests by means of discriminant analysis. Am J Clin Pathol 1969;52:320–8.
9. Chang YC, Yu CJ, Chang SC, Galvin JR, Liu HM, Hsiao CH, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. Radiology 2005;236:1067–75.
10. Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 1996;9:1736–42.
11. Odabasi Z, Cinel I. Consideration of severe coronavirus Disease 2019 as viral sepsis and potential use of immune checkpoint inhibitors. Crit Care Explor 2020;2:e0141.
12. Liu TY, Lee WJ, Tsai CM, Kuo KC, Lee CH, Hsieh KS, et al. Serum lactate dehydrogenase isoenzymes 4 plus 5 is a better biomarker than total lactate dehydrogenase for refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Neonatol 2018;59:501–6.
13. Konttinen A, Somer H, Auvinen S. Serum enzymes and isozymes: extrapulmonary sources in acute pulmonary embolism. Arch Intern Med 1974;133:243–6.
14. Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Am Rev Respir Dis 1988;137:796–800.
15. Ben SQ, Ni SS, Shen HH, Shi YX, Huang SB, Xu JH, Huang JF. The dynamic changes of LDH isoenzyme 3 and D-dimer following pulmonary thromboembolism in canine. Thromb Res 2007;120:575–83.
16. Hagadorn JE, Bloor CM, Yang MS. Elevated plasma activity of lactate dehydrogenase isoenzyme-3 (LDH3) in experimentally induced immunologic lung injury. Am J Pathol 1971;64:575–81.
17. Trujillo NP, Nutter D, Evans JM. The isoenzymes of lactic dehydrogenase: II. Pulmonary embolism, liver disease, the postoperative state, and other medical conditions. Arch Intern Med 1967;119:333–44.
18. Ringoir SM. Serum lactate dehydrogenase isozymes in human lung homotransplantation. Clin Chim Acta 1975;58:291–4.
19. Hagadorn JE, Mercola KE. Immunologic and morphologic studies of the acute effect of anti-lung serum. Exp Mol Pathol 1971;15:97–107.
20. Fu Y, Zhu R, Bai T, Han P, He Q, Jing M, et al. Clinical features of patients infected with coronavirus Disease 2019 with elevated liver biochemistries: A multicenter, retrospective study. Hepatology 2021;73:1509–20.
21. Chadalavada P, Padbidri V, Garg R, Alomari M, Babar A, Kewan T, et al. Transaminases are potential biomarkers of disease severity in COVID-19 patients: A single-center experience. Cureus 2020;12:e11555.
22. Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal liver tests in COVID-19: A retrospective observational cohort study of 1,827 patients in a major U.S. Hospital network. Hepatology 2020;72:1169–76.
23. Zhang Y, Xiao LS, Li P, Zhu H, Hu C, Zhang WF, et al. Clinical characteristics of patients with progressive and non-progressive coronavirus Disease 2019: evidence from 365 hospitalised patients in Honghu and Nanchang, China. Front Med (Lausanne) 2020;7:556818.
24. Sulejmani A, Galimberti E, Giacobone C, Milano A, Scopetta E, Intra J, et al. Baseline characteristics of COVID-19 Italian patients admitted to Desio Hospital, Lombardy: a retrospective study. Scand J Clin Lab Investig 2021;81:18–23.
25. Aloisio E, Chibireva M, Serafini L, Pasqualetti S, Falvella FS, Dolci A, Panteghini M. A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity. Arch Pathol Lab Med 2020;144:1457–64.
Sva prava zadržana (c) 2022 İlkay Ergenç
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.